TrialBritish journal of haematology2026

Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial.

Andrew Hall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.